CareDx Inc (CDNA), a precision medicine company developing and marketing diagnostic solutions for transplant patients, is charting an ambitious path forward, with a goal of reaching $500 million in annual revenue by 2027.
The company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey. It also provides genomics-driven insights for transplant patients in the United States, where approximately 46,000 transplants are performed annually. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a donor-derived cell-free DNA solution for heart transplant patients; and AlloSure Lung, a donor-derived cell-free DNA solution for lung transplant patients.
For comments and feedback: editorial@rttnews.com